Takeda Pharmaceutical trades at an attractively valued forward price-to-earnings of 29.8x for a global pharma with 186% free cash flow conversion and 31% analyst upside, but three consecutive earnings misses and weak revenue growth signal the business has not yet demonstrated the execution quality needed to close the valuation gap.
Thesis pillars
- Exceptional Free Cash Flow Conversion→Stable
- Analyst Consensus Significant Upside→Stable
- Consecutive Earnings Miss Record↑Improving
- +1 more pillar — see the Why tab for full reasoning
Takeda Pharmaceutical Company L (TAK) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Multiple concerning factors at $17.63: Consecutive earnings misses (3); Weak growth.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and... Read more
Sell if holding. Multiple concerning factors at $17.63: Consecutive earnings misses (3); Weak growth. Chart setup: Golden cross, above all MAs, RSI 53, MACD bullish. Score 5.5/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 75d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-08-15Recent Developments — Takeda Pharmaceutical Company L
Latest news
- NEWS TAK|Takeda Pharmaceutical Co Ltd|Price:17.095|Chg%:-0.655 - TradingKey — TradingKey neutral
- NEWS Takeda Pharmaceutical Company Limited 2026 Q4 - Results - Earnings Call Presentation (NYSE:TAK) 2026-05-13 - Seeking Alp — Seeking Alpha neutral
- NEWS What's Going On With Takeda Stock Wednesday? - Takeda Pharmaceutical Co (NYSE:TAK) - Benzinga — Benzinga neutral
- NEWS Earnings call transcript: Takeda’s Q4 2025 performance highlights resilience By Investing.com - Investing.com India — Investing.com India positive
- NEWS Earnings call transcript: Takeda’s Q4 2025 performance highlights resilience By Investing.com - Investing.com Canada — Investing.com Canada positive
Generated 2026-08-15T13:12:18Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $17.63: Consecutive earnings misses (3); Weak growth. Chart setup: Golden cross, above all MAs, RSI 53, MACD bullish. Prior stop was $16.93. Score 5.5/10, moderate confidence.
Take-profit target: $20.27 (+15.0% upside). Prior stop was $16.93. Stop-loss: $16.93.
Consecutive earnings misses (3); Weak growth.
Takeda Pharmaceutical Company L trades at a P/E of N/A (forward 33.3). TrendMatrix value score: 7.9/10. Verdict: Sell.
21 analysts cover TAK with a consensus score of 3.9/5.
What does Takeda Pharmaceutical Company L do?Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing...
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.